Literature DB >> 26874689

Histological Assessment of NAFLD.

Pierre Bedossa1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of histological lesions ranging from steatosis to a complex pattern with hepatocyte injury and inflammation in an appropriate clinical context. The disease has been artificially dichotomized into NAFL (steatosis) and NASH (steatosis with hepatocellular injury and inflammation), but it is increasingly clear that intermediate patterns may exist. More than NASH, the stage of fibrosis was shown to govern prognosis, and for such evaluation, a liver biopsy of adequate size and width is needed. Like for any other chronic liver diseases, semi-quantitative histologic scores have been proposed. They are not useful in clinical practice but concur to categorize homogeneous group of patients according to their histology. Pediatric NAFLD is a growing concern. While a subgroup of children may harbor different but characteristic histological patterns, most of them display a mixed pattern or features similar to the adults. Today, liver histology is the mainstay for clinical trials. Biopsy is used both for enrollment and for assessing benefit of clinical trials. End points such as reversion of NASH or regression of fibrosis are acceptable but require a clear histological definition.

Entities:  

Keywords:  Fibrosis; Liver biopsy; NAFLD; NASH

Mesh:

Substances:

Year:  2016        PMID: 26874689     DOI: 10.1007/s10620-016-4062-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  58 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 3.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

4.  Hepatocellular ballooning in NASH.

Authors:  Stephen Caldwell; Yoshihiro Ikura; Daniela Dias; Kosuke Isomoto; Akito Yabu; Christopher Moskaluk; Patcharin Pramoonjago; Winsor Simmons; Harriet Scruggs; Nicholas Rosenbaum; Timothy Wilkinson; Patsy Toms; Curtis K Argo; Abdullah M S Al-Osaimi; Jan A Redick
Journal:  J Hepatol       Date:  2010-06-25       Impact factor: 25.083

5.  Triglyceride accumulation protects against fatty acid-induced lipotoxicity.

Authors:  Laura L Listenberger; Xianlin Han; Sarah E Lewis; Sylvaine Cases; Robert V Farese; Daniel S Ory; Jean E Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

6.  Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.

Authors:  Heather M Patton; Katherine Yates; Aynur Unalp-Arida; Cynthia A Behling; Terry T-K Huang; Philip Rosenthal; Arun J Sanyal; Jeffrey B Schwimmer; Joel E Lavine
Journal:  Am J Gastroenterol       Date:  2010-04-06       Impact factor: 10.864

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

Authors:  Kanji Yamaguchi; Liu Yang; Shannon McCall; Jiawen Huang; Xing Xian Yu; Sanjay K Pandey; Sanjay Bhanot; Brett P Monia; Yin-Xiong Li; Anna Mae Diehl
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

9.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Aynur Unalp; Cynthia E Behling; Joel E Lavine; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

10.  Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.

Authors:  Elizabeth M Brunt; Sunil Ramrakhiani; Barry G Cordes; Brent A Neuschwander-Tetri; Christine G Janney; Bruce R Bacon; Adrian M Di Bisceglie
Journal:  Mod Pathol       Date:  2003-01       Impact factor: 7.842

View more
  17 in total

Review 1.  Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.

Authors:  Abdul M Oseini; Banumathi K Cole; Danny Issa; Ryan E Feaver; Arun J Sanyal
Journal:  Hepatol Int       Date:  2018-01-03       Impact factor: 6.047

2.  Combining a β3 adrenergic receptor agonist with alpha-lipoic acid reduces inflammation in male mice with diet-induced obesity.

Authors:  Zahraa Abdul Sater; Cheryl Cero; Anne E Pierce; Hannah J Lea; Houssein Abdul Sater; Kenneth Y Zhu; Naili Liu; Yinyan Ma; Oksana Gavrilova; Aaron M Cypess
Journal:  Obesity (Silver Spring)       Date:  2021-11-25       Impact factor: 9.298

Review 3.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

4.  Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.

Authors:  Aline de Conti; Volodymyr Tryndyak; Rose A Willett; Barbara Borowa-Mazgaj; Anna Watson; Ralph Patton; Sangeeta Khare; Levan Muskhelishvili; Greg R Olson; Mark I Avigan; Carl E Cerniglia; Sharon A Ross; Arun J Sanyal; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  FASEB J       Date:  2020-04-18       Impact factor: 5.191

5.  PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum.

Authors:  Habeeb Salameh; Muhannad Al Hanayneh; Maen Masadeh; Mohammed Naseemuddin; Tasnia Matin; Angelika Erwin; Ashwani K Singal
Journal:  J Clin Transl Hepatol       Date:  2016-07-08

Review 6.  Non-alcoholic fatty liver disease: An expanded review.

Authors:  Mark Benedict; Xuchen Zhang
Journal:  World J Hepatol       Date:  2017-06-08

7.  Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease.

Authors:  Thomas Karlas; Lara Weise; Stephanie Kuhn; Felix Krenzien; Matthias Mehdorn; David Petroff; Nicolas Linder; Alexander Schaudinn; Harald Busse; Volker Keim; Johann Pratschke; Johannes Wiegand; Katrin Splith; Moritz Schmelzle
Journal:  J Transl Med       Date:  2017-05-19       Impact factor: 5.531

8.  Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage.

Authors:  Mario Masarone; Valerio Rosato; Andrea Aglitti; Tommaso Bucci; Rosa Caruso; Teresa Salvatore; Ferdinando Carlo Sasso; Marie Francoise Tripodi; Marcello Persico
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

9.  A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity.

Authors:  Takuya Seike; Takuya Komura; Yoshiaki Shimizu; Hitoshi Omura; Tatsuo Kumai; Takashi Kagaya; Hajime Ohta; Atsuhiro Kawashima; Kenichi Harada; Shuichi Kaneko; Masashi Unoura
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

10.  An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.

Authors:  Zobair M Younossi; Azza Karrar; Mariaelena Pierobon; Aybike Birerdinc; Maria Stepanova; Dinan Abdelatif; Zahra Younoszai; Thomas Jeffers; Sean Felix; Kianoush Jeiran; Alex Hodge; Weidong Zhou; Fanny Monge; Lakshmi Alaparthi; Vikas Chandhoke; Zachary D Goodman; Emanuel F Petricoin
Journal:  BMC Med       Date:  2018-09-12       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.